The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

China Pharmaceutical Contract Manufacturing Services Market, 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    March 2020

  • Pages
    210

  • View Count
    983

Example Insights

China- Pharmaceutical-Contract-Manufacturing-Context China- Pharmaceutical-Contract-Manufacturing-List-Of-CMOs China- Pharmaceutical-Contract-Manufacturing-Distribution-by-location
China- Pharmaceutical-Contract-Manufacturing-Capacity-analysis China- Pharmaceutical-Contract-Manufacturing-Benchmarking China- Pharmaceutical-Contract-Manufacturing-Market-Forecast
China- Pharmaceutical-Contract-Manufacturing-Segmentation    

 

Overview

Small molecule drugs represent nearly 90% of pharmaceutical products available in the market. In fact, in 2019, the FDA’s Center for Drug Evaluation and Research approved 48 drugs, of which, 67% were small molecules. However, drug development and manufacturing is a cost intensive process, and is, at times, characterized by the need for advanced capabilities and specialized facilities, which are not possible for all developer companies to build in-house. This has compelled many of the smaller companies to outsource a significant part of their manufacturing operations to contract service providers. Pharmaceutical contract manufacturing organizations (CMOs) offer a wide range of services, ranging from process R&D, and clinical / commercial scale manufacturing of APIs, intermediates and FDFs. Some of the benefits of engaging manufacturing service providers include access to larger production capacities, cost savings (for innovator companies) and reductions in time-to-market. In this context, the advantages of outsourcing to emerging global regions, especially in Asia, are well known. A number of western drug developers have already demonstrated the preference to outsource their manufacturing operations to CMOs or CDMOs in China.

Over the past few decades, the pharmaceutical market in China has evolved into the second largest in the world; as per certain industry experts, it is estimated to surpass USD 300 billion by the end of 2020. Similarly, the contract manufacturing market in the region has also grown into a prominent and promising segment of the pharmaceutical industry. The relatively lower manufacturing costs, availability of cheap and skilled labor, and a supportive regulatory landscape, have led to the establishment of various pharmaceutical manufacturing facilities in China by both Chinese and non-China based service providers. The number of FDA approved API manufacturing facilities in the region has doubled during the period 2010-2019. In fact, as of October 2019, 13% of FDA approved pharmaceutical manufacturing facilities are situated in China. These service providers are focused on investing in the development of the necessary capabilities and capacity to stay ahead of the competition in this field. In light of the aforementioned facts, China has been one of the top preferences of pharmaceutical companies for API and FDF manufacturing projects, since the past few years. 

We believe that, the changing supply chain scenario due to the recent COVID-19 outbreak is likely to have a prominent impact on the global contract manufacturing industry, including China, in the short term. Having said that, the steps being taken by the pharma players and contract manufacturers are likely to help stakeholders absorb this impact. As pharma companies resume full-scale operation after the coronavirus outbreak, the demand for large-scale contract manufacturing is expected to increase significantly.

Scope of the Report

The “China Pharmaceutical Contract Manufacturing Services Market, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing market in China. The study also features a detailed analysis, highlighting the capabilities of pharmaceutical CMOs in this region. Amongst other elements, the report features:

  • A review of the current market landscape of companies offering pharmaceutical contract manufacturing services in China, along with information on year of establishment, company size, location of headquarters, type of product (active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs)), type of FDFs, type of primary packaging and number of manufacturing facilities.
  • A detailed landscape of the pharmaceutical manufacturing facilities in China, including an analysis based on location of these facilities, highlighting key manufacturing hubs.  
  • A brief discussion of various guidelines laid down by regulatory authorities in China for the manufacturing of pharmaceuticals. It also provides information on various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China.
  • Brief profiles of key players that offer a diverse range of capabilities for the manufacturing of pharmaceutical products in China. Each profile includes an overview of the company, information related to its pharmaceutical manufacturing service portfolio, details related to its manufacturing facilities, recent developments, and an informed future outlook. 
  • A review of the pharmaceutical manufacturing related initiatives of the top 10 big pharma players (shortlisted from the top companies of 2019 by revenues), featuring a [A] analysis by investments made, with detailed information on investments related to R&D centers and manufacturing facilities in established and emerging regions of China, [B] Harvey ball framework, presenting a summary of all initiatives, and [C] a heat map representation highlighting the yearly distribution of the initiatives undertaken by each company.
  • A case study of the key recent developments (including partnerships and acquisitions) pertaining to the manufacturing of pharmaceutical drugs, during 2014-2020 (till February), based on several parameters, such as year of partnership, type of partnership and geography.
  • A detailed capacity analysis based on the individual reactor capacities of various industry stakeholders, taking into consideration parameters, such as company size (small-sized, mid-sized, large and very large), and location of the manufacturing facility (Eastern China, Southern China and Northern China). 
  • A discussion on industry affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the evolution of this field. It also includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on industry dynamics.
  • A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes. 

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on various parameters, such as growth of the overall pharmaceutical drugs market in China, cost of goods sold, and direct manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] key geographical regions (Eastern China, Southern China, Northern China), [B] type of product (API and drug product), [C] type of drug product (solid, liquid / semi-solid, injectables, others), [D] scale of operation (clinical and commercial), [E] company size (small-sized, mid-sized, large / very large. To account for the uncertainties associated with the growth of the pharmaceutical drugs contract manufacturing market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in this study were also influenced by discussions conducted with stakeholders in this domain. All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the key insights captured in our research. The summary offers a high-level view on the likely evolution of pharmaceutical contract manufacturing services market in China, in the short-mid and long term.

Chapter 3 is a general introduction to various type of manufacturers engaged in the pharmaceutical domain. It also includes a brief overview on the concept of contract manufacturing and a general discussion on the evolution of contract services in the pharmaceutical industry. The chapter features an exhaustive list of services offered by CMOs. Further, it highlights the current contract manufacturing scenario in China, along with the advantages and disadvantages associated with choosing a China based CMO as a partner. 

Chapter 4 is a case study comparing the key characteristics of large and small molecule drugs, along with information on the steps involved in their respective manufacturing processes. In addition, it highlights the information on the key manufacturing challenges associated with small molecules and large molecules.

Chapter 5 provides an overview of the pharmaceutical contract manufacturing landscape of companies that claim to offer small molecule API, intermediate and FDF manufacturing services. It includes analysis based on a number of relevant parameters, such as year of establishment, company size, location of headquarters, type of product (APIs, intermediates and FDFs), type of FDFs, type of packaging (primary packaging and secondary packaging), and number of China-based manufacturing facilities.

Chapter 6 provides a detailed landscape of pharmaceutical manufacturing facilities in China. It includes analysis and map representations based on location of these facilities, highlighting key provinces as manufacturing hubs.  

Chapter 7 features a brief discussion on the regulatory guidelines related to the pharmaceutical manufacturing in China. It also highlights points related to the various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China.

Chapter 8 includes detailed profiles of key players that offer a diverse range of capabilities for the manufacturing of pharmaceutical products in China. Each profile features a brief overview of the company, details related to its manufacturing-related service portfolio, details related to its manufacturing facilities, recent developments, and an informed future outlook.

Chapter 9 provides a detailed analysis of pharmaceutical manufacturing related initiatives of the top 10 big pharma players (shortlisted from the top companies of 2019 by revenues), featuring a [A] facility investment analysis with detailed information on R&D centers and manufacturing facilities in established and emerging regions of China, [B] Harvey ball framework presenting the summary of manufacturing initiatives undertaken by big pharma players in China, and [C] heat map representation representing the year-wise distribution of the initiatives undertaken by each company.

Chapter 10 represents a case study of the key recent activities of the CMOs from 2017 to February 2020 (including partnerships and acquisitions) pertaining to the manufacturing of pharmaceutical drugs. It includes analysis based on several parameters, such as year of partnership, type of partnership and geographical activity of the partnerships.

Chapter 11 features an estimate of the overall installed reactor capacity of CMOs. The analysis based on the individual reactor capacities of various industry stakeholders, taking into consideration parameters, such as company size (small-sized, mid-sized, large and very large), and location of the manufacturing facility (Eastern China, Southern China and Northern China).

Chapter 12 presents a discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.

Chapter 13 features an elaborate market forecast analysis highlighting the likely growth of pharmaceutical contract manufacturing market in China, till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] key geographical regions (Eastern China, Southern China, Northern China), [B] type of product (API and drug product), [C] type of drug product (solid, liquid / semi-solid, injectables, others), [D] scale of operation (clinical and commercial), [E] company size (small-sized, mid-sized, large / very large). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

Chapter 14 highlights the effect of coronavirus outbreak on the global pharmaceutical industry. It includes a brief discussion on the short-term and long-term impact of COVID-19 upsurge on the supply chain and market opportunity for drug developers and CMOs. In addition, it includes a brief section on strategies and action plans that pharma companies are likely to adopt in order to prepare for supply chain disruptions in future. 

Chapter 15 is a summary of the overall report. It includes key takeaways related to research and analysis from the report in an infographic format.

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 17 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of the Pharmaceutical Contract Manufacturing 
3.3. Evolution of the Pharmaceutical Contract Manufacturing Industry
3.3.1. Traditional CMOs
3.3.2. Modern CMOs
3.4 Need for Outsourcing in the Pharmaceutical Industry
3.5. Services Offered by CMOs
3.6. Pharmaceutical Contract Manufacturing Scenario in China
3.7. Advantages and Challenges associated with Outsourcing Pharmaceutical Manufacturing to China-based CMOs

4. CASE STUDY: COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES
4.1. Chapter Overview
4.2. Small Molecule and Large Molecule Drugs / Therapies
4.2.1. Comparison of Key Characteristics
4.2.2. Comparison of Manufacturing Processes
4.2.3. Comparison of Key Manufacturing-related Challenges

5. MARKET OVERVIEW
5.1. Chapter Overview
5.2. Chinese Pharmaceutical CMOs with Manufacturing Facilities in China: List of Companies
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Type of Product (API and FDF)
5.2.4.1. Analysis by Type of Product and Location of Headquarters
5.2.5. Analysis by Highest Scale of Operation
5.2.6. Analysis by Type of FDF
5.2.6.1. Analysis by Type of Solid FDF
5.2.6.2. Analysis by Type of Liquid FDF
5.2.6.3. Analysis by Type of Powder FDF
5.2.6.4. Analysis by Type of Semi-Solid FDF
5.2.6.5. Analysis by Type of FDF and Region
5.2.7. Analysis by Type of Primary Packaging

5.3. Non-Chinese Pharmaceutical CMOs with Manufacturing Facilities in China: List of Companies
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters
5.3.4. Analysis by Type of Product (API and FDF)
5.3.4.1. Analysis by Type of Product and Region
5.3.5. Analysis by Highest Scale of Operation
5.3.6. Analysis by Type of FDF
5.3.6.1. Analysis by Type of Solid FDF
5.3.6.2. Analysis by Type of Liquid FDF
5.3.6.3. Analysis by Type of Powder FDF
5.3.6.5. Analysis by Type of FDF and Region

6. MANUFACTURING FACILITIES OF PHARMACEUTICAL CMOs IN CHINA
6.1. Chapter Overview
6.2. Pharmaceutical CMO Manufacturing Facilities in China
6.2.1. Facilities in Eastern China
6.2.1.1. Pharmaceutical CMO Manufacturing Facilities in Eastern China: Analysis by Location of Facility
6.2.1.2. Pharmaceutical CMO Manufacturing Facilities in Eastern China: Analysis by Company Size and Type of Product
6.2.2. Facilities in Northern China
6.2.2.1. Pharmaceutical CMO Manufacturing Facilities in Northern China: Analysis by Location of Facility
6.2.2.2. Pharmaceutical CMO Manufacturing Facilities in Northern China: Analysis by Company Size and Type of Product
6.2.3. Facilities in Southern China
6.2.3.1. Pharmaceutical CMO Manufacturing Facilities in Southern China: Analysis by Location of Facility
6.2.3.2. Pharmaceutical CMO Manufacturing Facilities in Southern China: Analysis by Company Size and Type of Product

7. PHARMACEUTICAL MANUFACTURING REGULATIONS IN CHINA
7.1. Chapter Overview
7.1.1. Health Authorities in China
7.1.2. Overview of Regulatory Guidelines in China

8. COMPANY PROFILES
8.1. Chapter Overview
8.2. 2Y-Chem
8.2.1. Company Overview
8.2.2. Service Portfolio
8.2.3. Recent Developments and Future Outlook

8.3. Aurisco Pharmaceutical
8.3.1. Company Overview
8.3.2. Service Portfolio
8.3.3. Recent Developments and Future Outlook

8.4. ChemPartner
8.4.1. Company Overview
8.4.2. Service Portfolio
8.4.4. Recent Developments and Future Outlook

8.5. Dorrapharma
8.5.1. Company Overview
8.5.2. Service Portfolio
8.5.4. Recent Developments and Future Outlook

8.6. Hubei Biocause Pharmaceutical
8.6.1. Company Overview
8.6.2. Service Portfolio
8.6.3. Recent Developments and Future Outlook

8.7. Infoark
8.7.1. Company Overview
8.7.2. Service Portfolio
8.7.3. Recent Developments and Future Outlook

8.8. Ningbo Menovo Pharmaceutical
8.8.1. Company Overview
8.8.2. Service Portfolio
8.8.3. Recent Developments and Future Outlook

8.9. Shandong Xinhua Pharmaceutical
8.9.1. Company Overview
8.9.2. Service Portfolio
8.9.3. Recent Developments and Future Outlook

8.10. Shanghai Acebright Pharmaceuticals
8.10.1. Company Overview
8.10.2. Service Portfolio
8.10.3. Recent Developments and Future Outlook

8.11. STA Pharmaceutical
8.11.1. Company Overview
8.11.2. Service Portfolio
8.11.3. Recent Developments and Future Outlook

8.12. Zhejiang Huahai Pharmaceutical
8.12.1. Company Overview
8.12.2. Service Portfolio
8.12.4. Recent Developments and Future Outlook

9. BIG PHARMA INITIATIVES IN CHINA
9.1. Chapter Overview
9.2. Big Pharma Players: List of Initiatives
9.2.1. Analysis by Number of Initiatives
9.2.2. Analysis by Year of Initiative
9.2.3. Analysis by Company and Year of Initiative
9.2.4. Analysis by Type of Initiative

9.3. Benchmark Analysis of Big Pharmaceutical Players
9.3.1. Harvey Ball Analysis: Summary of Investments Made
9.3.2. Geographical Analysis by Investments Made (Facility Specific)

10. CASE STUDY: RECENT PARTNERSHIP TRENDS
10.1. Chapter Overview
10.2. Partnership Models
10.3. CMOs with Manufacturing Facilities in China: List of Recent Partnerships
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Geography
10.4. CMOs with Manufacturing Facilities in China: Mapping Partnerships

11. CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. CMOs with Manufacturing Facilities in China: Installed Capacity
11.3.1. Analysis by Company Size
11.3.2. Analysis by Location of Chinese Manufacturing Facilities
11.3.2.1. Capacity Analysis: Eastern China
11.3.2.2. Capacity Analysis: Southcentral China
11.3.2.3. Capacity Analysis: Northern China

12. SWOT ANALYSIS
12.1. Chapter Overview
12.2 Strengths
12.3. Weakness
12.4. Opportunities
12.5. Threats
12.6. Comparison of SWOT Factors

13. MARKET FORECAST
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030
13.4. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography

13.4.1. Pharmaceutical Contract Manufacturing Services Market in Eastern China, 2020-2030
13.4.2. Pharmaceutical Contract Manufacturing Services Market in Southern China, 2020-2030
13.4.3. Pharmaceutical Contract Manufacturing Services Market in Northern China, 2020-2030

13.5. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Type of Product
13.5.1. API Contract Manufacturing Services Market in China, 2020-2030
13.5.1.1. API Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography

13.5.1.1.1. API Contract Manufacturing Services Market in Eastern China, 2020-2030
13.5.1.1.2. API Contract Manufacturing Services Market in Southern China, 2020-2030
13.5.1.1.3. API Contract Manufacturing Services Market in Northern China, 2020-2030

13.5.2. Drug Product Contract Manufacturing Services Market in China, 2020-2030
13.5.2.1. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography

13.5.2.1.1. Drug Product Contract Manufacturing Services Market in Eastern China, 2020-2030
13.5.2.1.2. Drug Product Contract Manufacturing Services Market in Southern China, 2020-2030
13.5.2.1.3. Drug Product Contract Manufacturing Services Market in Northern China, 2020-2030

13.5.2.2. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Distribution by Type of Drug Product
13.5.2.2.1. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Solid Drug Product
13.5.2.2.2. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Liquid and Semi Solid Drug Product
13.5.2.2.3. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Injectable Drug Product
13.5.2.2.4. Drug product Contract Manufacturing Services Market in China, 2020-2030: Share of Other Drug Products

13.6. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Scale of Operation
13.6.1. Clinical Scale Contract Manufacturing Services Market in China, 2020-2030
13.6.2. Commercial Scale Contract Manufacturing Services Market in China, 2020-2030

13.7. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Size of Manufacturers
13.7.1. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Small Companies
13.7.2. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Mid-sized Companies
13.7.3. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Large / Very Large Companies

13.8. Concluding Remarks

14. CASE STUDY: IMPACT OF CORONAVIRUS OUTBREAK
15.1. Chapter Overview
15.2. Evaluation of Impact of COVID-19 Outbreak

15.2.1. Initiatives and Opinions of Key Players
15.2.1.1. Wuxi AppTec
15.2.1.2. Porton Pharma Solutions
15.2.1.3. Lonza

15.2.2 Impact on China Pharmaceutical CMO Market Opportunity

15.3. Key Strategies to Adopt: A Bird’s Eye View
15.3.1. Immediate Steps
15.3.2. Short / Long Term Steps

15. CONCLUSION

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Outsourcing across Various Components of the Pharmaceutical Value Chain
Figure 3.2 Range of Services Offered by CMOs
Figure 4.1 Small Molecule and Large Molecule Drugs: Comparison of Key Characteristics
Figure 4.2 Small Molecules versus Large Molecule: Comparison of Manufacturing Process
Figure 5.1 Chinese Pharmaceutical CMOs: Distribution by Year of Establishment
Figure 5.2 Chinese Pharmaceutical CMOs: Distribution by Company Size
Figure 5.3 Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Region-wise)
Figure 5.4 Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Province-wise)
Figure 5.5 Chinese Pharmaceutical CMOs: Distribution by Type of Product
Figure 5.6 Chinese Pharmaceutical CMOs: Distribution by Type of Product Manufactured and Location of Headquarters
Figure 5.7 Chinese Pharmaceutical CMOs: Highest Scale of Operation
Figure 5.8 Chinese Pharmaceutical CMOs: Distribution by Type of FDF Manufactured
Figure 5.9 Chinese Pharmaceutical CMOs: Distribution by Type of Solid FDF Manufactured
Figure 5.10 Chinese Pharmaceutical CMOs: Distribution by Type of Liquid FDF Manufactured
Figure 5.11 Chinese Pharmaceutical CMOs: Distribution by Type of Powder FDF Manufactured
Figure 5.12 Chinese Pharmaceutical CMOs: Distribution by Type of Semi-Solid FDF Manufactured
Figure 5.13 Chinese Pharmaceutical CMOs: Distribution by Type of FDF Manufactured and Geography
Figure 5.14 Chinese Pharmaceutical CMOs: Distribution by Type of Primary Packaging
Figure 5.15 Non-Chinese Pharmaceutical CMOs: Distribution by Year of Establishment
Figure 5.16 Non-Chinese Pharmaceutical CMOs: Distribution by Company Size
Figure 5.17 Non-Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Region-wise)
Figure 5.18 Non-Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Country-wise)
Figure 5.19 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Product
Figure 5.20 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Product Manufactured and Geography
Figure 5.21 Non-Chinese Pharmaceutical CMOs: Distribution by Highest Scale of Operation
Figure 5.22 Non-Chinese Pharmaceutical CMOs: Distribution by Type of FDF Manufactured
Figure 5.23 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Solid FDF Manufactured
Figure 5.24 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Liquid FDF Manufactured
Figure 5.25 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Powder FDF Manufactured
Figure 5.26 Non-Chinese Pharmaceutical CMOs: Distribution by Type of FDF Manufactured and Geography
Figure 6.1 Geographical Map Representation: Pharmaceutical CMO Manufacturing Facilities in Eastern China
Figure 6.2 Pharmaceutical CMO Manufacturing Facilities in Eastern China: Distribution by Company Size and Type of Product
Figure 6.3 Geographical Map Representation: Pharmaceutical CMO Manufacturing Facilities in Northern China
Figure 6.4 Pharmaceutical CMO Manufacturing Facilities in Northern China: Distribution by Company Size and Type of Product
Figure 6.5 Geographical Map Representation: Pharmaceutical CMO Manufacturing Facilities in Southern China
Figure 6.6 Pharmaceutical CMO Manufacturing Facilities in Southern China: Distribution by Company Size and Type of Product
Figure 7.1 Health Authorities in China and Affiliated Organizations of the CFDA
Figure 7.2 Organizational Structure of the CDE
Figure 7.3 Responsibilities of the Contract Giver
Figure 7.4 Important Aspects of the Contract
Figure 9.1 Big Pharma Benchmarking: Distribution by Number of Initiatives
Figure 9.2 Big Pharma Players: Distribution by Year of Initiative
Figure 9.3 Big Pharma Players: Distribution by Company and Year of Initiative
Figure 9.4 Big Pharma Players: Distribution by Type of Initiative
Figure 9.5 Harvey Ball Analysis: Summary of Investments Made
Figure 9.6 Big Pharma Players: Geographical Distribution by Investments Made (Facility Specific)
Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-February 2020
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Local and International Distribution
Figure 10.4 Partnerships Landscape: Distribution by Year of Collaboration, Type of Collaboration and Collaborator
Figure 11.1 Pharmaceutical Contract Manufacturing Installed Capacity in China: Distribution by Size of CMOs
Figure 11.2 Pharmaceutical Contract Manufacturing Installed Capacity in China: Distribution by Location of Facility
Figure 11.3 Capacity Analysis: Contract Pharmaceutical Capacity in Eastern China
Figure 11.4 Capacity Analysis: Contract Pharmaceutical Capacity in Southcentral China
Figure 11.5 Capacity Analysis: Contract Pharmaceutical Capacity in Northern China
Figure 12.1 China Pharmaceutical Contract Manufacturing Services Market: SWOT Analysis
Figure 12.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 13.1 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Figure 13.2 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030, Distribution by Geography: Base Scenario (USD Billion)
Figure 13.3 Pharmaceutical Contract Manufacturing Services Market in Eastern China, 2020-2030: Base Scenario (USD Billion)
Figure 13.4 Pharmaceutical Contract Manufacturing Services Market in Southern China, 2020-2030: Base Scenario (USD Billion)
Figure 13.5 Pharmaceutical Contract Manufacturing Services Market in Northern China, 2020-2030: Base Scenario (USD Billion)
Figure 13.6 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030, Distribution by Type of Product (USD Billion)
Figure 13.7 API Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Figure 13.8 API Contract Manufacturing Services Market in China, Distribution by Geography, 2020-2030: Base Scenario (USD Billion)
Figure 13.9 API Contract Manufacturing Services Market in Eastern China, 2020-2030: Base Scenario (USD Billion)
Figure 13.10 API Contract Manufacturing Services Market in Southern China, 2020-2030: Base Scenario (USD Billion)
Figure 13.11 API Contract Manufacturing Services Market in Southern China, 2020-2030: Base Scenario (USD Billion)
Figure 13.12 Drug Product Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Figure 13.13 Drug Product Contract Manufacturing Services Market in China, Distribution by Geography, 2020-2030: Base Scenario (USD Billion)
Figure 13.14 Drug Product Contract Manufacturing Services Market in Eastern China, 2020-2030: Base Scenario (USD Billion)
Figure 13.15 Drug Product Contract Manufacturing Services Market in Southern China, 2020-2030: Base Scenario (USD Billion)
Figure 13.16 Drug Product Contract Manufacturing Services Market in Northern China, 2020-2030: Base Scenario (USD Billion)
Figure 13.17 Drug Product Contract Manufacturing Services Market in China, Distribution by Type of Drug Product, 2020-2030, Base Scenario (USD Billion)
Figure 13.18 Drug Product Contract Manufacturing Services Market in China, 2020-2030, Share of Solid Drug Product: Base Scenario (USD Billion)
Figure 13.19 Drug Product Contract Manufacturing Services Market in China, 2020-2030, Share of Liquid and Semi Solid Drug Product: Base Scenario (USD Billion)
Figure 13.20 Drug Product Contract Manufacturing Services Market in China, 2020-2030, Share of Injectable Drug Product: Base Scenario (USD Billion)
Figure 13.21 Drug product Contract Manufacturing Services Market in China, 2020-2030, Share of Other Drug Products: Base Scenario (USD Billion)
Figure 13.22 Pharmaceutical Contract Manufacturing Services Market in China, Distribution by Scale of Operation, 2020-2030, Base Scenario (USD Billion)
Figure 13.23 Clinical Scale Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Figure 13.24 Commercial Scale Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Figure 13.25 Pharmaceutical Contract Manufacturing Services Market in China, Distribution by Size of Manufacturers, 2020-2030, Base Scenario (USD Billion)
Figure 13.26 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030, Share of Small Companies: Base Scenario (USD Billion)
Figure 13.27 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030, Share of Mid-sized Companies: Base Scenario (USD Billion)
Figure 13.28 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030, Share of Large / Very Large Companies: Base Scenario (USD Billion)
Figure 14.1 Pharmaceutical Contract Manufacturing Services Market in China, 2015-2030: COVID Impact Scenario (USD Billion)
Figure 14.2 Financial Leadership vs Strategic Leadership Matrix: Evaluation of Preparedness of Companies
Figure 15.2 China Pharmaceutical Contract Manufacturing Services Market: Key Takeaways

List Of Tables

Table 3.1 Preferred Locations for Pharmaceutical CMO / CDMO Services
Table 4.1 Small Molecule and Large Molecule Drugs: Comparison of Development Characteristics
Table 5.1 List of Chinese Pharmaceutical CMOs: Information on Year of Establishment, Company Size, Location of Headquarters, Type of Product and Scale of Operation
Table 5.2 List of Chinese Pharmaceutical CMOs: Information on Type of FDF Manufactured
Table 5.3 List of Chinese Pharmaceutical CMOs: Information on Packaging Service
Table 5.4 List of Non-Chinese Pharmaceutical CMOs: Information on Year of Establishment, Company Size, Headquarter Location and Type of Product and Scale of Operation
Table 5.5 List of Chinese Pharmaceutical CMOs: Information on Type of FDF Manufactured
Table 6.1 Pharmaceutical CMO Manufacturing Facilities in China: Information on Location of Facilities
Table 6.2 Pharmaceutical CMO Manufacturing Facilities in Eastern China: Information on Location of Facilities (Province-Wise) and Core Capability
Table 6.3 Pharmaceutical CMO Manufacturing Facilities in Northern China: Information on Location of Facilities (Province-Wise) and Core Capability
Table 6.4 Pharmaceutical CMO Manufacturing Facilities in Southern China: Information on Location of Facilities (Province-Wise) and Core Capability
Table 8.1 2-Y Chem: Company Overview
Table 8.2 2Y-Chem: Pharmaceutical R&D and Manufacturing Service Offerings
Table 8.3 Aurisco Pharmaceutical: Company Overview
Table 8.4 Aurisco Pharmaceutical: R&D and Pharmaceutical Manufacturing Service Offerings
Table 8.5 ChemPartner: Company Overview
Table 8.6 ChemPartner: R&D and Pharmaceutical Manufacturing Service Offerings
Table 8.7 Dorrapharma: Company Overview
Table 8.8 Dorrapharma: R&D and Pharmaceutical Manufacturing Service Offerings
Table 8.9 Hubei Biocasue Pharmaceutical: Company Overview
Table 8.10 Hubei Biocasue Pharmaceutical: R&D and Pharmaceutical Manufacturing Service Offerings
Table 8.11 Infoark: Company Overview
Table 8.12 Ningbo Menovo Pharmaceutical: Company Overview
Table 8.13 Shandong Xinhua Pharmaceutical: Company Overview
Table 8.14 Shandong Xinhua Pharmaceutical: Pharmaceutical R&D and Manufacturing Service Offerings
Table 8.15 Shanghai Acebright Pharmaceuticals: Company Overview
Table 8.16 STA Pharmaceutical: Company Overview
Table 8.17 STA Pharmaceutical: Pharmaceutical R&D and Manufacturing Service Offerings
Table 8.18 Zhejiang Huahai Pharmaceutical: Company Overview
Table 8.19 Zhejiang Huahai Pharmaceutical: R&D and Pharmaceutical Manufacturing Service Offerings
Table 9.1 Big Pharmaceutical Players: List of Initiatives
Table 10.1 List of Partnerships, 2014-Q1 2019
Table 10.2 List of Partnerships: Information on Headquarter Location of Parent and Partner Company
Table 11.1 China Pharmaceutical Contract Manufacturing Installed Capacity: Average Capacity by Size of CMOs (Sample Data Set)
Table 11.2 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Size of CMOs
Table 11.3 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Chinese Manufacturing Facility(s)
Table 16.1 Chinese Pharmaceutical CMOs: Distribution by Year of Establishment
Table 16.2 Chinese Pharmaceutical CMOs: Distribution by Company Size
Table 16.3 Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Region-wise)
Table 16.4 Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Province-wise)
Table 16.5 Chinese Pharmaceutical CMOs: Distribution by Type of Product
Table 16.6 Chinese Pharmaceutical CMOs: Distribution by Highest Scale of Operation
Table 16.7 Chinese Pharmaceutical CMOs: Distribution by Type of FDF Manufactured
Table 16.8 Chinese Pharmaceutical CMOs: Distribution by Type of Solid FDF Manufactured
Table 16.9 Chinese Pharmaceutical CMOs: Distribution by Type of Liquid FDF Manufactured
Table 16.10 Chinese Pharmaceutical CMOs: Distribution by Type of Powder FDF Manufactured
Table 16.11 Chinese Pharmaceutical CMOs: Distribution by Type of Semi-Solid FDF Manufactured
Table 16.12 Chinese Pharmaceutical CMOs: Distribution by Type of Primary Packaging
Table 16.13 Non-Chinese Pharmaceutical CMOs: Distribution by Year of Establishment
Table 16.14 Non-Chinese Pharmaceutical CMOs: Distribution by Company Size
Table 16.15 Non-Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Region-wise)
Table 16.16 Non-Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Country-wise)
Table 16.17 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Product
Table 16.18 Non-Chinese Pharmaceutical CMOs: Distribution by Highest Scale of Operation
Table 16.19 Non-Chinese Pharmaceutical CMOs: Distribution by Type of FDF Manufactured
Table 16.20 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Solid FDF Manufactured
Table 16.21 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Liquid FDF Manufactured
Table 16.22 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Powder FDF Manufactured
Table 16.23 Pharmaceutical CMO Manufacturing Facilities in Eastern China:
Table 16.24 Pharmaceutical CMO Manufacturing Facilities in Eastern China: Distribution by Type of Product
Table 16.25 Pharmaceutical CMO Manufacturing Facilities in Northern
Table 16.26 Pharmaceutical CMO Manufacturing Facilities in Northern China: Distribution by Type of Product
Table 16.27 Pharmaceutical CMO Manufacturing Facilities in Southern China: Distribution by Company Size
Table 16.28 Pharmaceutical CMO Manufacturing Facilities in Southern China: Distribution by Type of Product
Table 16.29 Big Pharma Players: Distribution by Number of Initiatives
Table 16.30 Big Pharma Players: Distribution by Year of Initiative
Table 16.31 Big Pharma Players: Distribution by Type of Initiative
Table 16.33 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-February 2020
Table 16.34 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.35 Partnerships and Collaborations: Local and International Distribution
Table 16.36 Pharmaceutical Contract Manufacturing Installed Capacity in China: Distribution by Size of CMOs
Table 16.37 Pharmaceutical Contract Manufacturing Installed Capacity in China: Distribution by Location of Facility
Table 16.38 Capacity Analysis: Contract Pharmaceutical Capacity in Eastern China
Table 16.39 Capacity Analysis: Contract Pharmaceutical Capacity in Southcentral China
Table 16.40 Capacity Analysis: Contract Pharmaceutical Capacity in Northern China
Table 16.41 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Table 16.42 Pharmaceutical Contract Manufacturing Services Market in China, 2025 and 2030, Distribution by Geography: Base Scenario (USD Billion)
Table 16.43 Pharmaceutical Contract Manufacturing Services Market in Eastern China, 2020-2030: Base Scenario (USD Billion)
Table 16.44 Pharmaceutical Contract Manufacturing Services Market in Southern China, 2020-2030: Base Scenario (USD Billion)
Table 16.45 Pharmaceutical Contract Manufacturing Services Market in Northern China, 2020-2030: Base Scenario (USD Billion)
Table 16.46 Pharmaceutical Contract Manufacturing Services Market in China, 2025 and 2030, Distribution by Type of Product (USD Billion)
Table 16.47 API Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Table 16.48 API Contract Manufacturing Services Market in China, Distribution by Geography, 2025 and 2030: Base Scenario (USD Billion)
Table 16.49 API Contract Manufacturing Services Market in Eastern China, 2020-2030: Base Scenario (USD Billion)
Table 16.50 API Contract Manufacturing Services Market in Southern China, 2020-2030: Base Scenario (USD Billion)
Table 16.51 API Contract Manufacturing Services Market in Northern China, 2020-2030: Base Scenario (USD Billion)
Table 16.53 Drug Product Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Table 16.52 Drug Product Contract Manufacturing Services Market in China, Distribution by Geography, 2025 and 2030: Base Scenario (USD Billion)
Table 16.54 Drug Product Contract Manufacturing Services Market in Eastern China, 2020-2030: Base Scenario (USD Billion)
Table 16.55 Drug Product Contract Manufacturing Services Market in Southern China, 2020-2030: Base Scenario (USD Billion)
Table 16.56 Drug Product Contract Manufacturing Services Market in Northern China, 2020-2030: Base Scenario (USD Billion)
Table 16.57 Drug Product Contract Manufacturing Services Market in China, Distribution by Type of Drug Product, 2025 and 2030, Base Scenario (USD Billion)
Table 16.58 Drug Product Contract Manufacturing Services Market in China, 2020-2030, Share of Solid Drug Product: Base Scenario (USD Billion)
Table 16.59 Drug Product Contract Manufacturing Services Market in China, 2020-2030, Share of Liquid and Semi Solid Drug Product: Base Scenario (USD Billion)
Table 16.60 Drug Product Contract Manufacturing Services Market in China, 2020-2030, Share of Injectable Drug Product: Base Scenario (USD Billion)
Table 16.61 Drug Product Contract Manufacturing Services Market in China, 2020-2030, Share of Other Drug Products: Base Scenario (USD Billion)
Table 16.62 Pharmaceutical Contract Manufacturing Services Market in China, Distribution by Scale of Operation, 2025 and 2030, Base Scenario (USD Billion)
Table 16.63 Clinical Scale Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Table 16.64 Commercial Scale Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Table 16.65 Pharmaceutical Contract Manufacturing Services Market in China, Distribution by Size of Manufacturers, 2025 and 2030, Base Scenario (USD Billion)
Table 16.66 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Small Companies: Base Scenario (USD Billion)
Table 16.67 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Mid-Sized Companies: Base Scenario (USD Billion)
Table 16.68 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Large / Very Large Companies: Base Scenario (USD Billion)

Listed Companies

  1. 2Y-Chem
  2. 3Waypharm
  3. ABA Chemicals
  4. AbbVie
  5. Aescu Pharma
  6. Agno Pharma
  7. Allychem
  8. Amgen
  9. Anhui Biochem Biopharmaceutical
  10. Anqiu Lu’an Pharmaceutical
  11. Antengene 
  12. Apeloa
  13. APIchem 
  14. APICMO
  15. Ark Biosciences
  16. Asymchem
  17. Aurisco Pharmaceutical
  18. Avery Chemical
  19. Beijing Kawin Technology
  20. Beijing Lunarsun Pharmaceutical
  21. Beijing Mediking Biopharm
  22. Beta Pharma
  23. BioDuro
  24. BioLingus
  25. BLD Pharm
  26. Bristol-Myers Squibb
  27. Broad Pharmaceutical
  28. C & O Pharmaceutical Technology
  29. CARBOGEN AMCIS
  30. Catalent Pharma Solutions
  31. Changzhou Carbochem
  32. Changzhou Keylab Chemical
  33. ChemFuture PharmaTech
  34. ChemPartner
  35. Chemsigma International
  36. Chemspec Chemicals
  37. Chemwill Asia
  38. China Pharmaceutical Research and Development Center
  39. Chinese Peptide
  40. Chiral Quest
  41. Chongqing Huabang Shengkai Pharmaceutical
  42. Chongqing Pharmaceutical Research Institute
  43. Cipla
  44. Codexis
  45. ComWin International
  46. DC Chemicals 
  47. Dishman Group
  48. Dizal Pharmaceutical
  49. Dorrapharma
  50. DSL Chemicals
  51. Enantiotech
  52. Enbridge PharmTech
  53. EOC Pharma
  54. Esteve Huayi Pharmaceutical 
  55. FarmaSino Pharmaceutical 
  56. Fine Industries
  57. Flamma
  58. Fountainbridge
  59. Fresenius Kabi 
  60. GIHI CHEMICALS
  61. Gilead Sciences
  62. GlaxoSmithKline
  63. Hangzhou DayangChem
  64. Hangzhou Hysen Pharma
  65. Hangzhou Panyu Chemical
  66. Hangzhou Pharmco
  67. Hangzhou Rongda Pharm & Chem
  68. HangZhou Think Chemical
  69. HD Biosciences
  70. Hebei BRANT Pharmaceutical 
  71. Hebei Jiheng Pharmaceutical
  72. Hetero
  73. Hovione
  74. Huayi Pharmaceuticals
  75. Hubei Biocause Pharmaceutical
  76. Hybio Pharmaceutical
  77. Impact Therapeutics
  78. Infoark
  79. Jiangsu Allyrise Pharmaceutical
  80. Jiangsu Baozong & Baoda Pharmachem
  81. Jiangsu Hansyn Pharmaceutical
  82. Jiangsu Quality Horizons Pharmtech
  83. Jiangxi Fushine Pharmaceutical
  84. JOINN Laboratories
  85. Junye Pharmaceutical
  86. Kingchem Life Sciences
  87. Krka
  88. Laviana Pharma
  89. LEAPChem
  90. Lianhetech
  91. Lianhua Technology
  92. Lonza 
  93. Luna Chemicals
  94. Medichem
  95. Merck
  96. Nanjing Pharmatechs
  97. NFTZ Alchem International
  98. Ningbo Menovo Pharmaceutical
  99. Novartis
  100. Novasep
  101. Pfizer
  102. Pfizer CentreOne
  103. PharmaBlock Sciences
  104. PharmAgra Labs
  105. Phoenix Molecular Designs
  106. Pi chemicals
  107. Piramal Pharma Solutions
  108. Porton Pharma Solutions
  109. Prisun Pharmachem
  110. Qidong Accela ChemBio
  111. Qingdao Kingway Pharmtech
  112. Quantum
  113. Raybow Pharm
  114. Roche
  115. SAGECHEM 
  116. Saniver 
  117. Sanofi
  118. SciAnda (Changshu) Pharmaceuticals
  119. Seacross Pharmaceuticals
  120. Shandong Keyuan Pharmaceutical 
  121. Shandong Luxi Pharmaceutical
  122. Shandong Xinhua Pharmaceutical
  123. Shanghai Acebright Pharmaceuticals 
  124. Shanghai Ansion pharma Technology
  125. Shanghai Fosun Pharmaceutical
  126. Shanghai Hohance Chemical
  127. Shanghai Pansopharm Technology
  128. Shanghai Ruiyi Medical Tech
  129. Shenzhen Jianyuan Pharmaceutical Technology 
  130. Siegfried 
  131. Sihuan Pharmaceutical
  132. Sinolite 
  133. STA Pharmaceutical
  134. Sundia MediTech
  135. Sunwell
  136. Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial
  137. Suzhou Novartis Pharmaceutical Technology
  138. Tai Heng Industry
  139. TCI (Shanghai) Development
  140. Tesaro 
  141. TIEN (Tianjin) Pharmaceutical
  142. Topharman Shanghai
  143. Venturepharma 
  144. Vesino
  145. Vifor Pharma 
  146. Vitruvias Therapeutic
  147. ViWA
  148. Viwit Pharmaceuticals
  149. Wisdom Pharmaceutical
  150. WuXi AppTec
  151. Xianju pharma
  152. XINXIANG BEST PHARMACEUTICAL 
  153. YaoPharma
  154. Yiling Pharmaceutical
  155. Zhejiang Candorly Pharmaceutical
  156. Zhejiang Changming Pharmaceutical
  157. Zhejiang Dongjian Pharmaceutical 
  158. Zhejiang Excel Pharmaceutical 
  159. Zhejiang Haizhou Pharmaceutical
  160. Zhejiang Hisun Pharmaceutical
  161. Zhejiang Huahai Pharmaceutical
  162. Zhejiang Jiuzhou Pharmaceutical
  163. Zhejiang Langhua Pharmaceutical
  164. Zhejiang Tianyu Pharmaceutical
  165. Zhejiang Yongtai Technology
  166. ZHIWE ChemTech

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com